KR20010029723A - Low Substituted Hydroxypropylcellulose and Solid Drug - Google Patents

Low Substituted Hydroxypropylcellulose and Solid Drug Download PDF

Info

Publication number
KR20010029723A
KR20010029723A KR1020000026310A KR20000026310A KR20010029723A KR 20010029723 A KR20010029723 A KR 20010029723A KR 1020000026310 A KR1020000026310 A KR 1020000026310A KR 20000026310 A KR20000026310 A KR 20000026310A KR 20010029723 A KR20010029723 A KR 20010029723A
Authority
KR
South Korea
Prior art keywords
hydroxypropyl cellulose
low
tablet
substituted hydroxypropyl
solid formulation
Prior art date
Application number
KR1020000026310A
Other languages
Korean (ko)
Inventor
히로야스 고꾸보
Original Assignee
카나가와 치히로
신에쓰 가가꾸 고교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카나가와 치히로, 신에쓰 가가꾸 고교 가부시끼가이샤 filed Critical 카나가와 치히로
Publication of KR20010029723A publication Critical patent/KR20010029723A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00Preparation of cellulose ethers
    • C08B11/02Alkyl or cycloalkyl ethers
    • C08B11/04Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
    • C08B11/08Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals with hydroxylated hydrocarbon radicals; Esters, ethers, or acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

PURPOSE: To improve the wettability and significantly shorten the disintegration time of a solid formulation even in the same amount added and formulating composition as those of a conventional formulation by using a specific hydroxypropyl cellulose having a low degree of substitition. CONSTITUTION: A hydroxypropyl cellulose having a low degree of substitution of 0.04-0.1 average number of substituted mol of hydroxypropoxyl groups based on the glucose unit (C6H10O5) is used. The object to which the objective hydroxypropyl cellulose is applied may be a solid formulation requiring the shortening of the disintegration time and, e.g. the hydroxylpropyl cellulose can be added at the time of granulating a tableting powder in the production of a tablet or mixed with the tableting powder after the granulation. Besides the abode hydroxypropyl cellulose, for example, a crude drug, a lubricant such as magnesium stearate, an excipient such as corn starch or lactose or other disintegrating agents or binders may be contained in the solid formulation. When the above hydroxypropyl cellulose is used as a binder for granulation, the amount thereof added is preferably 3-15 wt.% based on the solid formulation. after drying.

Description

저치환도 히드록시프로필셀룰로오스 및 고형 제제{Low Substituted Hydroxypropylcellulose and Solid Drug}Low Substituted Hydroxypropylcellulose and Solid Drug

본 발명은, 습윤성을 개선할 수 있어서 종래와 동일한 첨가량, 배합 조성에 서도 고형 제제의 붕괴 시간을 상당히 단축시킬 수 있는 저치환도 히드록시프로필셀룰로오스 및 이를 포함하는 고형 제제에 관한 것이다.The present invention relates to a low-substituted hydroxypropyl cellulose and a solid preparation containing the same, which can improve the wettability and can significantly reduce the disintegration time of the solid preparation even in the same amount and combination composition as before.

저치환도 히드록시프로필셀룰로오스는 의약품 첨가제로서 대부분의 공정서에 수록되어 붕괴제로서 범용되는 것 중의 하나이다. 이들 붕괴제는 정제, 과립제, 캡슐제 등의 고형 제제의 붕괴 시간을 단축시킬 목적으로 첨가된다.Low-substituted hydroxypropyl cellulose is one of the most commonly used disintegrants listed in most process documents as a pharmaceutical additive. These disintegrants are added for the purpose of shortening the disintegration time of solid preparations such as tablets, granules, capsules and the like.

정제의 붕괴는 약물의 생체이용률을 규정하는 중요한 인자 중 하나이다. 소화관으로부터의 약물의 흡수는 정제의 붕괴, 약물의 소화관액에 의한 용해에 이어서 발생한다고 되어 있다. 최근, 약물의 유효 이용 및 동등성 평가의 관점에서, 정제 등의 고형 제제의 용출 시험이 재검토되고 있으며, 용출이 빠른 제제는 유효성 또는 동등성을 보장한다는 생각이 주류이다. 따라서, 보다 빠르게 붕괴되는 정제가 요망되고 있다.Disintegration of tablets is one of the important factors that define the bioavailability of the drug. Absorption of the drug from the digestive tract is said to occur following the disintegration of the tablet and dissolution of the drug by the digestive tract fluid. In recent years, from the viewpoint of the effective use and equivalence evaluation of drugs, dissolution testing of solid preparations such as tablets has been reviewed, and the main idea is that fast-dissolving preparations guarantee efficacy or equivalence. Therefore, there is a demand for tablets that disintegrate faster.

붕괴제로서는 카르복시메틸셀룰로오스칼슘, 가교 카르복시메틸셀룰로오스나트륨, 저치환도 히드록시프로필셀룰로오스 등의 셀룰로오스 유도체, 카르복시메틸스타치나트륨, 부분 α화 전분 등의 전분 유도체, 가교 폴리비닐피로피돈 등의 합성 고분자가가 널리 사용되고 있다. 이들 붕괴제의 선택은 각각의 붕괴제의 붕괴력(팽윤력), 성형성, 흡습성, 착색 안정성 및 적용하는 약물과의 배합 적성에 의해 판단된다.Examples of disintegrating agents include synthetic polymers such as cellulose derivatives such as carboxymethyl cellulose calcium, cross-linked carboxymethyl cellulose sodium and low-substituted hydroxypropyl cellulose, starch derivatives such as carboxymethyl starch sodium and partially α-starch, and cross-linked polyvinylpyrrolidone. Ga is widely used. The choice of these disintegrants is judged by the disintegration force (swelling force), moldability, hygroscopicity, coloring stability and compounding suitability of the respective disintegrating agents.

특히, 저치환도 히드록시프로필셀룰로오스는 비이온성으로 흡습성이 낮아, 착색 안정성이 우수하고, 대부분의 약제에 대하여 배합 적성이 우수하다는 등의 이점을 가지고 있으나, 약제의 종류, 처방에 따라서는 다른 첨가제와 비교하여 붕괴 시간을 목적 시간까지 단축시킬 수 없는 경우도 있어서 그 개선이 요망되어 왔다.In particular, low-substituted hydroxypropyl cellulose has the advantages of nonionicity, low hygroscopicity, excellent coloring stability, and excellent formulation suitability for most drugs, but other additives depending on the type of drug and the prescription Compared with other cases, the decay time cannot be shortened to the target time, and the improvement has been desired.

분말 입자로 구성되어 있는 정제의 붕괴 메카니즘은 소화관액 등의 액체(물)가 정제 내부로 모세관을 통하여 진입하고, 이어서 수용성 물질이 용해하거나 붕괴제 등이 물에 젖음으로써 팽윤하는 입자의 효과에 의해, 구성 입자가 분산함으로써 달성된다. 따라서, 정제 내부로의 물의 진입이 정제 붕괴의 제1 단계가 된다.The disintegration mechanism of the tablet composed of powder particles is caused by the effect of particles in which liquid (water), such as digestive tract fluid, enters into the tablet through the capillary, and then swells by dissolving a water-soluble substance or wetting of the disintegrating agent. This is achieved by dispersing the constituent particles. Thus, the entry of water into the tablet becomes the first stage of tablet collapse.

이 정제 내부로의 물의 진입 속도는, 하기 와쉬번(Washburn)식에 표시되는 것과 같이, 정제에 관한 요인 (R), 시험액에 관한 요인 (γ, η), 양자에 관한 요인 (θ)이 복잡하게 관련되어 있다 (제제 설계법 (1), 지인 서관, P507, 1971).The rate of entry of water into the tablet is complicated by factors (R) related to purification, factors (γ and η) related to the test solution, and factors (θ) related to both, as shown by the following Washburn equation. (Design formulation method (1), acquaintances' library, P507, 1971).

L2={(Rγcosθ)/(2η)}tL 2 = {(Rγcosθ) / (2η)} t

(식 중, L은 시간 t에서 젖은 모세관의 길이, R은 모세관의 반경, γ은 용액의 표면 장력, η은 용액의 점도, θ는 고체-액체 계면의 접촉각을 나타낸다.)Where L is the length of the wet capillary at time t, R is the radius of the capillary, γ is the surface tension of the solution, η is the viscosity of the solution, and θ is the contact angle of the solid-liquid interface.

정제의 붕괴 시간은 약제의 종류, 배합량 등에 의해 좌우되지만, 목적으로 하는 정제의 크기, 약제 배합량 등의 제약하에, 목적으로 하는 붕괴 시간을 달성하는 것이 곤란한 제제도 적지 않다. 정제를 빠르게 붕괴시키는 일반적 수법으로서는 붕괴제의 첨가량의 증가, 정제 내부의 공극율의 증가 등을 생각할 수 있다. 그러나, 붕괴제의 첨가량을 증가시키는 방법은 정제의 부피를 증가시키기 때문에 개선 효과에 한계가 있는 반면, 공극율을 증가시키는 방법은 분말을 압축하여 정제에 성형할 때의 성형압을 저하시키면 되지만, 정제 경도가 저하되는 등의 문제점이 있다.Although the disintegration time of a tablet depends on the kind of chemical | medical agent, a compounding quantity, etc., there are not many formulations which are difficult to achieve the target disintegration time under the constraint of the target tablet size, a chemical compounding quantity, and the like. As a general technique for rapidly disintegrating tablets, an increase in the amount of disintegrant added, an increase in porosity inside the tablet, and the like can be considered. However, the method of increasing the amount of disintegrant has a limitation in improving effect because it increases the volume of the tablet, while the method of increasing the porosity may reduce the molding pressure when compacting the powder to form the tablet. There is a problem that the hardness is lowered.

정제의 붕괴 시간은, 정제 조성, 붕괴제의 배합량 등이 동일하고, 즉 정제 내부의 공극 (모세관 반경)이 동일하고 그 환경 (시험액)이 동일하면, 전술의 와쉬번식에 의해 습윤성(고체-액체 계면의 접촉각)에 지배된다는 것을 알 수 있다.When the tablet disintegration time is the same in the tablet composition, the compounding amount of the disintegrating agent, etc., that is, the voids (capillary radius) in the tablet are the same and the environment (test solution) is the same, the wettability (solid-liquid) is obtained by the above-described wash propagation. The contact angle of the interface).

저치환도 히드록시프로필셀룰로오스는, 기씽어(Gissinger)의 보고(Drug Dev. Ind. Pharm, 6 (5), 511-536, 1980)에서 볼 수 있듯이 다른 첨가제에 비해 습윤성이 낮다 (접촉각이 높다). 예를 들면, 저치환도 히드록시프로필셀룰로오스는 50˚인 것에 대하여, 정제 등의 성형성을 높일 목적으로 첨가되는 미결정 셀룰로오스는 약 20。, 가교 카르복시메틸셀룰로오스나트륨은 0。, 카르복시메틸스타치나트륨은 0。, 부분 α화 전분으로는 0。, 가교 폴리비닐피로피돈은 34。로 습윤성에 있어서 뒤떨어져 있다.Low-substituted hydroxypropyl cellulose has a lower wettability than other additives (high contact angle), as seen in Gissinger's report (Drug Dev. Ind. Pharm, 6 (5), 511-536, 1980). ). For example, while the low-substituted hydroxypropyl cellulose is 50 °, the microcrystalline cellulose added for the purpose of improving the formability of tablets is about 20 °, and the cross-linked carboxymethyl cellulose sodium is 0 ° and carboxymethyl starch sodium. Is 0 °, 0 ° and partially crosslinked polyvinylpyrrolidone is 34 °, which is inferior in wettability.

본 발명은 습윤성을 개선할 수 있어서 종래와 동일한 첨가량, 배합 조성에 서도 고형 제제의 붕괴 시간을 상당히 단축시킬 수 있는 저치환도 히드록시프로필셀룰로오스 및 이를 포함하는 고형 제제를 제공하는 것을 목적으로 한다.An object of the present invention is to provide a low-substituted hydroxypropyl cellulose and a solid preparation containing the same, which can improve the wettability and can significantly reduce the disintegration time of the solid preparation even in the same amount and blending composition as before.

본 발명자들은 이러한 문제점을 해결하기 위해서 예의 검토한 결과, 글루코오스 단위 당 히드록시프로폭실기의 평균 치환 몰수가 0.04 내지 0.1인 저치환도 히드록시프로필셀룰로오스 및 이를 포함하는 고형 제제가, 습윤성을 개선할 수 있어서 종래와 동일한 첨가량, 배합 조성에서도 고형성제의 붕괴 시간을 상당히 단축시킬 수 있다는 것을 밝혀내어 본 발명을 완성하기에 이르렀다.The present inventors have diligently studied to solve these problems, and as a result, a low-substituted hydroxypropyl cellulose having a mean substitution mole number of hydroxypropoxyl group per glucose unit of 0.04 to 0.1 and a solid preparation containing the same may improve wettability. It was found that the disintegration time of the solid-forming agent can be significantly shortened even in the same amount of additives and compounding composition as before, and the present invention has been completed.

본 발명의 저치환도 히드록시프로필셀룰로오스는 특개소 48-38858호 공보, 특개소 57-53100호 공보에 개시되는 것과 같은 공지의 방법에 의해서 합성할 수 있다.The low-substituted hydroxypropyl cellulose of the present invention can be synthesized by known methods such as those disclosed in Japanese Patent Application Laid-Open Nos. 48-38858 and 57-53100.

일반적으로, 히드록시프로필셀룰로오스란 글루코오스 단위 (C6H10O5) 당 히드록시프로폭실기의 평균 치환 몰수가 2.0 내지 4.2인 것을 말하며, 평균 치환 몰수가 0.11 내지 0.39인 것은 저치환도 히드록시프로필셀룰로오스라 한다.In general, hydroxypropyl cellulose means that the average number of moles of hydroxypropoxyl groups per glucose unit (C 6 H 10 O 5 ) is 2.0 to 4.2, and the average number of moles of substitution of 0.11 to 0.39 is low-substituted hydroxy. It is called propyl cellulose.

한편, 본 발명의 저치환도 히드록시프로필셀룰로오스에서의 히드록시프로폭실기의 평균 치환 몰수는 글루코오스 단위 당 0.04 내지 0.1의 범위가 바람직하다. 히드록시프로폭실기는 습윤성에 대해서는 소수성의 효과를 나타내어, 히드록시프로폭실기의 치환량이 낮으면 낮을수록 친수성이 되어 습윤성이 개선되는 반면, 붕괴제로서의 팽윤력은 저하된다. 따라서, 히드록시프로폭실기의 평균 치환 몰수가 글루코오스 단위 당 0.04 미만이면 팽윤력이 크게 저하되어 바람직하지 못한 반면, 0.1을 초과하면 기존의 저치환도 히드록시프로필셀룰로오스와 동등한 습윤성이 되어 버린다. 또, 평균 치환 몰수의 제어는 알칼리셀룰로오스와 반응시키는 프로필렌옥사이드 등의 히드록시프로필화제의 첨가량을 조절함으로써 용이하게 달성된다.On the other hand, the average substituted mole number of the hydroxypropoxyl group in the low-substituted hydroxypropyl cellulose of the present invention is preferably in the range of 0.04 to 0.1 per glucose unit. The hydroxypropoxyl group exhibits a hydrophobic effect on the wettability. The lower the substitution amount of the hydroxypropoxyl group is, the more hydrophilic the wettability is and the wettability as the disintegrating agent is lowered. Therefore, if the average substituted mole number of the hydroxypropoxyl group is less than 0.04 per glucose unit, the swelling force is greatly lowered, which is not preferable. If the average substitution mole number of the hydroxypropoxyl group is more than 0.1, wettability equivalent to that of the existing low-substituted hydroxypropyl cellulose becomes. Moreover, control of an average substitution mole number is easily achieved by adjusting the addition amount of hydroxypropylating agents, such as propylene oxide made to react with alkali cellulose.

글루코오스 단위 당 평균 치환 몰수는 일본 약국방의 저치환도 히드록시프로필셀룰로오스의 정량법에 따라, 히드록시프로폭실기의 치환%를 구하고, 이것을 환산함으로써 구할 수 있다.The average number of substituted moles per unit of glucose can be obtained by calculating the% substitution of the hydroxypropoxyl group in accordance with the method of quantifying low-substituted hydroxypropyl cellulose of the Japanese pharmacy room, and converting this.

본 발명의 저치환도 히드록시프로필셀룰로오스가 적용되는 대상은, 붕괴 시간의 단축이 요구되고 있는 고형 제제라면 어느 것에도 적용된다. 예를 들면 정제의 제조에 있어서는 타정(打錠) 분말의 조립시에 첨가하거나, 조립 후의 타정 분말에 혼합할 수 있다. 또한, 과립제의 제조에 있어서는 조립 조성에 첨가할 수 있고, 캡슐제의 제조에 있어서는 캡슐 충전 분말에 혼합 배합할 수 있다.The object to which the low-substituted hydroxypropyl cellulose of the present invention is applied is applied to any solid preparation for which shortening of the disintegration time is required. For example, in manufacture of a tablet, it can add at the time of granulation of a tableting powder, or can mix with the tableting powder after granulation. In addition, it can add to granulation composition in manufacture of granules, and can mix and mix with a capsule filling powder in manufacture of a capsule.

고형 제제는 본 발명의 저치환도 히드록시프로필셀룰로오스 이외에, 예를 들면 주약(主藥), 스테아린산마그네슘 등의 활택제, 콘스타치 또는 젖당 등의 부형제, 그 밖의 붕괴제 또는 결합제 등을 포함할 수 있다. 즉, 본 발명의 저치환도 히드록시프로필셀룰로오스를 사용하여도 종래의 배합 조성을 사용할 수 있다.In addition to the low-substituted hydroxypropyl cellulose of the present invention, the solid preparation may include, for example, a lubricant, a lubricant such as magnesium stearate, an excipient such as corn starch or lactose, other disintegrating agents or a binder, and the like. . That is, even if the low substitution hydroxypropyl cellulose of this invention is used, a conventional compounding composition can be used.

본 발명의 저치환도 히드록시프로필셀룰로오스는 조립용 결합제로서 사용하는 경우는 건조 후의 고형 제제에 대하여 3 내지 15 중량% 첨가하는 것이 바람직하고, 조립 후의 타정 분말 또는 캡슐 충전 분말에 혼합하는 경우는 3 내지 10 중량% 첨가하는 것이 바람직하고, 부형제로서 사용하는 경우는 30 중량% 이상 첨가하는 것이 바람직하다. 즉, 종래와 동일한 배합량의 범위에서 사용할 수 있다.When used as a binder for granulation, the low-substituted hydroxypropyl cellulose of the present invention is preferably added in an amount of 3 to 15% by weight based on the solid formulation after drying, and when mixed with a tableting powder or capsule-filled powder after granulation, It is preferable to add 10 to 10 weight%, and when using as an excipient, it is preferable to add 30 weight% or more. That is, it can use in the range of the same compounding quantity conventionally.

이상과 같이 제조된 고형 제제는 제제학상 허용되는 수법, 예를 들면 필름코팅 또는 장용(腸溶) 코팅 등을 할 수 있다.The solid preparation prepared as described above may be subjected to a pharmaceutically acceptable method, for example, film coating or enteric coating.

이하에, 본 발명은 실시예 및 비교예를 통해 더욱 상세히 설명되지만, 본 발명은 이들 실시예의 기재에 한정되는 것은 아니다.In the following, the present invention will be described in more detail through examples and comparative examples, but the present invention is not limited to the description of these examples.

〈실시예 1〉<Example 1>

(습윤 시간의 측정)(Measurement of Wetting Time)

증류수 50 ㎖를 넣은 100 ㎖ 비이커에 시료 500 mg을 투입하고, 시료가 수면에서 습윤할 때까지의 시간을 측정하였다.500 mg of the sample was put into a 100 ml beaker containing 50 ml of distilled water, and the time until the sample was wet from the water was measured.

(타정 분말의 조제)(Preparation of tableting powder)

아세토아미노펜 (미분, 야마모토 가가꾸 고교사 제품) 400 g, 결합제로서 히드록시프로필메틸셀룰로오스 (TC-5E, 신에쓰 가가꾸 고교사 제품) 20 g을 정제수 265 g에 용해한 수용액을 소형 유동층 조립 장치 (Multiplex MP-01, 파우렉스사 제품)를 사용하여 통상법에 따라서 분무함으로써 조립 분말을 조제하였다.A small fluidized bed granulation apparatus (400 g of acetoaminophen (pulverized powder, manufactured by Yamamoto Chemical Co., Ltd.) and an aqueous solution of 20 g of hydroxypropylmethylcellulose (TC-5E, manufactured by Shin-Etsu Chemical Co., Ltd.) in 265 g of purified water as a binder. Granulated powder was prepared by spraying in accordance with a conventional method using Multiplex MP-01, manufactured by Faurex.

(저치환도화)(Low substitution)

저치환도 히드록시프로필셀룰로오스의 합성 공정에서 반응에 사용하는 프로필렌옥사이드를 삭감하고, 이하 통상의 조건으로 세정, 건조, 분쇄하였다. 얻어진 분말의 히드록시프로폭실기의 평균 치환 몰수는 글루코오스 단위 당 0.1이었다. 또한, 분체 물성은 후술하는 비교예 1에서 사용한 LH-11과 동등하였다.The propylene oxide used for reaction in the synthesis process of low-substituted hydroxypropyl cellulose was reduced, and it wash | cleaned, dried, and grind | pulverized on the following conditions normally. The average substituted mole number of the hydroxypropoxy group of the obtained powder was 0.1 per glucose unit. In addition, powder physical properties were equivalent to LH-11 used in Comparative Example 1 described later.

(정제의 조제)(Preparation of tablet)

상기 아세토아미노펜 조립 분말 285 g과 저치환도 히드록시프로필셀룰로오스(히드록시프로폭실기의 평균 치환 몰수는 0.1) 15 g을 잘 혼합하고, 그 후 활택제로서 스테아린산마그네슘 (SM-1000, 사카이 가가꾸 고교사 제품) 6 g을 혼합하여 타정 분말로 하였다. 타정은 회전식 타정기 (RT-S15K-T35, 기꾸수이 세이사꾸쇼 제품)으로 직경 9 mm, 12 mmR의 공이를 사용하고, 타정압 157 MPa, 1정 306 mg이 되도록 타정하였다.285 g of the acetoaminophen granulated powder and 15 g of a low-substituted hydroxypropyl cellulose (the average substituted mole number of the hydroxypropoxy group is 0.1) are mixed well, and then magnesium stearate (SM-1000, Sakai Chemical) as a lubricant. 6 g of high school product) was mixed to obtain a tableting powder. The tableting was a rotary tableting machine (RT-S15K-T35, manufactured by Kikusui Seisakusho Co., Ltd.) using a ball of 9 mm in diameter and 12 mm R, and tableted to a tablet pressure of 157 MPa and one tablet of 306 mg.

(물성의 평가)(Evaluation of physical property)

얻어진 정제는 일본 약국방의 붕괴 시험법에 준하여 시험액으로서 정제수를사용하고, 디스크를 사용하지 않는 조건하에 붕괴 시간을 측정하였다. 저치환도히드록시프로필셀룰로오스의 습윤 시간과 정제의 붕괴 시간을 표 1에 나타내었다.The obtained tablets were subjected to the disintegration test method of the Japanese Pharmacy Chamber, using purified water as the test liquid, and the disintegration time was measured under the condition that no disk was used. Table 1 shows the wetting time and the disintegration time of the low-substituted hydroxypropyl cellulose.

〈비교예 1〉<Comparative Example 1>

실시예 1에서 조정한 아세토아미노펜 조립 분말과 저치환도 히드록시프로필셀룰로오스 (LH-11, 신에쓰 가가꾸 고교사 제품, 히드록시프로폭실기의 평균 치환 몰수는 0.26)를 사용하여 실시예 1과 동일한 조성, 조건으로 타정하였다. 얻어진 저치환도 히드록시프로필셀룰로오스의 습윤 시간과 정제의 붕괴 시간을 표 1에 나타내었다.Example 1 using acetoaminophen granulated powder adjusted in Example 1 and low-substituted hydroxypropyl cellulose (LH-11, Shin-Etsu Chemical Co., Ltd., the average number of moles of hydroxypropoxyl group is 0.26) It was compressed in the same composition and conditions. Table 1 shows the wetting time and the disintegration time of the obtained low-substituted hydroxypropyl cellulose.

〈실시예 2〉<Example 2>

(저치환도화)(Low substitution)

실시예 1과 동일하게 합성하여 얻어진 분말의 히드록시프로폭실기의 평균 치환 몰수는 글루코오스 단위 당 0.05이었다. 또한, 분체 물성은 비교예 1에서 사용한 LH-11과 동등하였다.The average substituted mole number of the hydroxypropoxyl group of the powder synthesize | combined similarly to Example 1 was 0.05 per glucose unit. In addition, powder physical properties were equivalent to LH-11 used in Comparative Example 1.

(정제의 조제)(Preparation of tablet)

실시예 1에서 조제한 아세토아미노펜 조립말을 사용하여 실시예 1과 동일한 조성, 동일한 타정 조건으로 타정하였다. 얻어진 저치환도 히드록시프로필셀룰로오스의 습윤 시간과 정제의 붕괴 시간을 표 1에 나타내었다.Using the acetoaminophene granules prepared in Example 1, the same composition and tableting conditions as in Example 1 were tableted. Table 1 shows the wetting time and the disintegration time of the obtained low-substituted hydroxypropyl cellulose.

〈실시예 3〉<Example 3>

(저치환도화)(Low substitution)

실시예 1과 동일하게 합성하여 얻어진 분말의 히드록시프로폭실기의 평균 치환 몰수는 글루코오스 단위 당 0.09이었다. 또한, 분체 물성은 비교예 1에서 사용한 LH-11과 동등하였다.The average substituted mole number of the hydroxypropoxyl group of the powder synthesize | combined similarly to Example 1 was 0.09 per glucose unit. In addition, powder physical properties were equivalent to LH-11 used in Comparative Example 1.

(정제의 조제)(Preparation of tablet)

실시예 1에서 조제한 아세토아미노펜 조립말을 사용하여 실시예 1과 동일한 조성, 동일한 타정 조건으로 타정하였다. 얻어진 저치환도 히드록시프로필셀룰로오스의 습윤 시간과 정제의 붕괴 시간을 표 1에 나타내었다.Using the acetoaminophene granules prepared in Example 1, the same composition and tableting conditions as in Example 1 were tableted. Table 1 shows the wetting time and the disintegration time of the obtained low-substituted hydroxypropyl cellulose.

〈비교예 2〉<Comparative Example 2>

(저치환도화)(Low substitution)

실시예 1과 동일하게 합성하여 얻어진 분말의 히드록시프로폭실기의 평균 치환 몰수는 글루코오스 단위 당 0.03이었다. 또한, 분체 물성은 비교예 1에서 사용한 LH-11와 동등하였다.The average substituted mole number of the hydroxypropoxyl group of the powder synthesize | combined similarly to Example 1 was 0.03 per glucose unit. In addition, powder physical properties were equivalent to LH-11 used in Comparative Example 1.

(정제의 조제)(Preparation of tablet)

실시예 1에서 조제한 아세토아미노펜 조립 분말을 사용하고 실시예 1과 동일한 조성, 조건으로 타정하였다. 얻어진 저치환도 히드록시프로필셀룰로오스의 습윤 시간과 정제의 붕괴 시간을 표 1에 나타내었다.The acetoaminophene granulated powder prepared in Example 1 was used, and the same composition and conditions as in Example 1 were compressed. Table 1 shows the wetting time and the disintegration time of the obtained low-substituted hydroxypropyl cellulose.

히드록시프로필셀룰로오스Hydroxypropyl cellulose 정제refine 히드록시프로폭실기의 평균치환 몰수 / 글루코오스 단위Average Substitution Moles of Hydroxypropoxyl Groups / Glucose Units 습윤 시간Wetting time 붕괴 시간Decay time 실시예 1Example 1 0.10.1 4.9 초4.9 seconds 1 분 44 초1 minute 44 seconds 실시예 2Example 2 0.050.05 2.3 초2.3 seconds 2 분 4 초2 minutes 4 seconds 실시예 3Example 3 0.090.09 3.3 초3.3 sec 1 분 47 초1 minute 47 seconds 비교예 1Comparative Example 1 0.260.26 11.2 초11.2 sec 5 분 30 초5 minutes 30 seconds 비교예 2Comparative Example 2 0.030.03 0.8 초0.8 sec 4 분 21 초4 minutes 21 seconds

〈실시예 4〉<Example 4>

(정제의 조제)(Preparation of tablet)

실시예 1의 저치환도 히드록시프로필셀룰로오스 90 g과 카콘탕 엑기스 분말(카콘탕 건조 엑기스 분말 F, 알프스 야꾸힝 고교사 제품) 210 g을 잘 혼합하고, 그 후 활택제로서 스테아린산마그네슘 (SM-1000, 사카이 가가꾸 고교사 제품) 3 g을 혼합하여 타정 분말로 하였다. 타정은 회전식 타정기 (RT-S15K-T35, 기꾸수이 세이사꾸쇼 제품)으로 직경 9 mm, 12 mmR의 공이를 사용하여 타정압 142 MPa, 1정 303 mg이 되도록 타정하였다. 저치환도 히드록시프로필셀룰로오스의 습윤 시간과 정제의 붕괴 시간을 표 2에 나타내었다.90 g of the low-substituted hydroxypropyl cellulose of Example 1 and 210 g of chacontang extract powder (cacontang dry extract powder F, Alps Yakuching High School Co., Ltd.) were mixed well, and then magnesium stearate (SM-) was used as a lubricant. 1000 g of Sakai Kagaku Kogyo Co., Ltd.) was mixed to obtain a tableting powder. The tableting was a rotary tableting machine (RT-S15K-T35, manufactured by Kikusui Seisakusho Co., Ltd.) and tableted to a tablet pressure of 142 MPa and one tablet of 303 mg using a ball of 9 mm diameter and 12 mmR. Table 2 shows the wetting time and the disintegration time of the low-substituted hydroxypropyl cellulose.

〈실시예 5〉<Example 5>

실시예 2의 저치환도 히드록시프로필셀룰로오스를 사용하여 실시예 4와 동일하게 정제를 조제하고, 붕괴 시간을 측정하였다. 결과를 표 2에 나타내었다.The tablet was prepared like Example 4 using the low substitution hydroxypropyl cellulose of Example 2, and the disintegration time was measured. The results are shown in Table 2.

〈실시예 6〉<Example 6>

실시예 3의 저치환도 히드록시프로필셀룰로오스를 사용하여 실시예 4와 동일하게 정제를 조제하고, 붕괴 시간을 측정하였다. 결과를 표 2에 나타내었다.Tablets were prepared in the same manner as in Example 4 using the low-substituted hydroxypropyl cellulose of Example 3, and the disintegration time was measured. The results are shown in Table 2.

〈비교예 3〉<Comparative Example 3>

비교예 1에서 사용한 LH-11을 사용하고, 실시예 4와 동일하게 정제를 조제하여, 붕괴 시간을 측정하였다. 결과를 표 2에 나타내었다.Using LH-11 used in Comparative Example 1, tablets were prepared in the same manner as in Example 4, and the disintegration time was measured. The results are shown in Table 2.

〈비교예 4〉<Comparative Example 4>

비교예 2에서 사용한 저치환도 히드록시프로필셀룰로오스를 사용하고, 실시예 4와 동일하게 정제를 조제하여, 붕괴 시간을 측정하였다. 결과를 표 2에 나타내었다.Using the low-substituted hydroxypropyl cellulose used in Comparative Example 2, tablets were prepared in the same manner as in Example 4, and the disintegration time was measured. The results are shown in Table 2.

히드록시프로필셀룰로오스Hydroxypropyl cellulose 정제refine 히드록시프로폭실기의 평균치환 몰수 / 글루코오스 단위Average Substitution Moles of Hydroxypropoxyl Groups / Glucose Units 습윤 시간Wetting time 붕괴 시간Decay time 실시예 4Example 4 0.10.1 4.9 초4.9 seconds 27.5 분27.5 minutes 실시예 5Example 5 0.050.05 2.3 초2.3 seconds 33.2 분33.2 minutes 실시예 6Example 6 0.090.09 3.3 초3.3 sec 29.7 분29.7 minutes 비교예 3Comparative Example 3 0.260.26 11.2 초11.2 sec 47.5 분47.5 minutes 비교예 4Comparative Example 4 0.030.03 0.8 초0.8 sec 66.6 분66.6 minutes

실시예에서 알 수 있는 바와 같이, 본 발명의 저치환도 히드록시프로필셀룰로오스는 기존의 제품 (비교예 1)에 비해, 상당히 습윤성이 개선되어, 정제로 만들었을 경우의 붕괴 시간도 상당히 단축되었다.As can be seen from the examples, the low-substituted hydroxypropyl cellulose of the present invention has significantly improved wettability compared to the conventional product (Comparative Example 1), and the collapse time when made into tablets is also significantly shortened.

히드록시프로폭실기의 평균 치환 몰수가 극단적으로 낮아지면 (비교예 2, 4) 습윤성은 개선되지만, 정제로 만들었을 경우의 붕괴 시간의 단축 효과는 대폭 감소하거나 반대로 연장되었다. 이것은 평균 치환 몰수를 극단적으로 낮게 하였기 때문에 그 팽윤력도 대폭 감소한 결과라고 생각된다.Extremely low average substitution moles of hydroxypropoxyl groups (Comparative Examples 2 and 4) improve the wettability, but the shortening effect of the disintegration time when made into tablets is greatly reduced or vice versa. This is because the average number of molar substitutions is extremely low, and it is considered that the swelling force is also a result of drastically decreasing.

본 발명의 저치환도 히드록시프로필셀룰로오스 및 이를 포함하는 고형 제제는 습윤성을 개선할 수 있어, 종래와 동일한 첨가량, 배합 조성에서도 고형 제제의 붕괴 시간을 상당히 단축시킬 수 있다.The low-substituted hydroxypropyl cellulose of the present invention and the solid preparation including the same can improve the wettability, and can significantly shorten the collapse time of the solid preparation even in the same amount and blending composition as before.

Claims (2)

글루코오스 단위 당 히드록시프로폭실기의 평균 치환 몰수가 0.04 내지 0.1인 것을 특징으로 하는 저치환도 히드록시프로필셀룰로오스.Low-substituted hydroxypropyl cellulose, characterized in that the average number of moles of hydroxypropoxyl groups per glucose unit is 0.04 to 0.1. 제1항 기개의 저치환도 히드록시프로필셀룰로오스를 포함하는 것을 특징으로 하는 고형 제제.A solid preparation comprising a low-substituted hydroxypropyl cellulose of claim 1.
KR1020000026310A 1999-05-18 2000-05-17 Low Substituted Hydroxypropylcellulose and Solid Drug KR20010029723A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP99-136788 1999-05-18
JP11136788A JP2000327701A (en) 1999-05-18 1999-05-18 Hydroxypropyl cellulose having low degree of substitution and solid formulation

Publications (1)

Publication Number Publication Date
KR20010029723A true KR20010029723A (en) 2001-04-16

Family

ID=15183542

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020000026310A KR20010029723A (en) 1999-05-18 2000-05-17 Low Substituted Hydroxypropylcellulose and Solid Drug

Country Status (3)

Country Link
JP (1) JP2000327701A (en)
KR (1) KR20010029723A (en)
CN (1) CN1203896C (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6700083B2 (en) * 2016-03-30 2020-05-27 株式会社ファンケル Orally fast disintegrating tablets
JP6700084B2 (en) * 2016-03-30 2020-05-27 株式会社ファンケル Coated granules
WO2018021265A1 (en) 2016-07-27 2018-02-01 沢井製薬株式会社 Additive composition for orally disintegrating tablet
JP6651638B2 (en) 2016-09-06 2020-02-19 沢井製薬株式会社 Orally disintegrating tablet additive composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR860003006A (en) * 1984-10-23 1986-05-19 고사까 유우따로오 Medical hard capsules and preparation method thereof
JPH0269501A (en) * 1988-09-02 1990-03-08 Daicel Chem Ind Ltd Aminoethylated water soluble high polymer and production thereof
JPH09268126A (en) * 1996-04-04 1997-10-14 Nisshin Flour Milling Co Ltd Preparation for treating digestive ulcer
KR19980702193A (en) * 1995-02-14 1998-07-15 페라 스타르크;요헨 카르크 Solid Active Compound Formulations
KR20000062477A (en) * 1999-01-18 2000-10-25 카나가와 치히로 Low Substituted Hydroxypropyl Cellulose

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR860003006A (en) * 1984-10-23 1986-05-19 고사까 유우따로오 Medical hard capsules and preparation method thereof
JPH0269501A (en) * 1988-09-02 1990-03-08 Daicel Chem Ind Ltd Aminoethylated water soluble high polymer and production thereof
KR19980702193A (en) * 1995-02-14 1998-07-15 페라 스타르크;요헨 카르크 Solid Active Compound Formulations
JPH09268126A (en) * 1996-04-04 1997-10-14 Nisshin Flour Milling Co Ltd Preparation for treating digestive ulcer
KR20000062477A (en) * 1999-01-18 2000-10-25 카나가와 치히로 Low Substituted Hydroxypropyl Cellulose

Also Published As

Publication number Publication date
CN1273861A (en) 2000-11-22
JP2000327701A (en) 2000-11-28
CN1203896C (en) 2005-06-01

Similar Documents

Publication Publication Date Title
KR101565621B1 (en) Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
JP3302682B2 (en) Tablet using phosphate binding polymer
US7749536B2 (en) Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
EP1886673B1 (en) Solid dosage form of enteric solid dispersion and method for producing the same
EP2155159B1 (en) Robust rapid disintegration tablet formulation
KR100794427B1 (en) Direct compression polymer tablet core
KR101442862B1 (en) Solid medicinal preparation containing mannitol or lactose
US20080102117A1 (en) Base material for dry direct tableting comprising low-substituted hydroxypropyl cellulose
TW200825107A (en) Low-substituted hydroxypropylcellulose powder and method for producing the same
KR20110105341A (en) Low-substituted hydroxypropylcellulose and solid preparation comprising the same
KR20070104257A (en) The solid preparation comprising the enteric-coated solid dispersion
JP2013521244A (en) Oral pharmaceutical composition containing dabigatran etexilate
JP5258223B2 (en) Solid preparation of enteric solid dispersion and method for producing the same
CN109793715B (en) Apixaban oral solid preparation and preparation method thereof
KR20050043765A (en) Controlled release tablets of metformin
KR102518794B1 (en) Alkyl cellulose for use in tableting and solid preparation comprising same
EA016579B1 (en) Solid pharmaceutical composition comprising irbesartan hydrochloride and process for manufacture thereof
KR101421330B1 (en) A disintegrating tablet
KR20010029723A (en) Low Substituted Hydroxypropylcellulose and Solid Drug
EP3697392A1 (en) Tablets comprising tamsulosin and solifenacin
JP3746062B2 (en) Solid preparation and method for producing the same
JP2000229855A (en) Pravastatin sodium tablet
JPH092953A (en) Balofloxacin pharmaceutical preparation
JP4034472B2 (en) Low substituted hydroxypropylcellulose and solid preparations
EP1020184A1 (en) Sustained release tablets containing bupropion hydrochloride

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application